Search Results

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG.

Under the latest teaming between the two companies, who have worked together since 2010, Novartis will pay $180 million upfront to PeptiDream to find new radioligand therapies.

Astellas Pharma Inc. (TOKYO: 4503, President and CEO: Naoki Okamura, “Astellas”) and PeptiDream Inc. (TOKYO: 4587, President and CEO: Patrick C. Reid, “PeptiDream”) today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas.

First-in-human PET imaging study of 64Cu-PD-32766 for patients with clear cell renal cell carcinoma were initiated.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination of the second targeted peptide radiopharmaceutical clinical development candidate arising from their strategic partnership with RayzeBio, Inc., (“RayzeBio”), a privately held California-based targeted radiopharmaceutical company developing innovative cancer drugs.

The Japanese biopharma will receive $40 million upfront from Genetech for R&D of its macrocyclic peptide-radioisotope drug conjugates, with another $1 billion on the line in milestone payments.